<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139575">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01935882</url>
  </required_header>
  <id_info>
    <org_study_id>LOPRIM-1</org_study_id>
    <nct_id>NCT01935882</nct_id>
  </id_info>
  <brief_title>Low Dose Primaquine for Clearance of Gametocytes</brief_title>
  <acronym>LOPRIM</acronym>
  <official_title>A Double Blind Randomized Controlled Trial to Assess the Efficacy and Safety of Low Dose Primaquine for Clearance of Gametocytes in Asymptomatic Individuals Infected With P. Falciparum in Burkina Faso</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>London School of Hygiene and Tropical Medicine</source>
  <oversight_info>
    <authority>Burkina Faso: Regulatory Authority</authority>
    <authority>United Kingdom: London School of Hygiene &amp; Tropical Medicine</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primaquine (PQ) is currently the only available drug that can clear mature transmission
      stages of P. falciparum parasites. PQ was previously shown to clear gametocytes that persist
      after artemisinin-combination therapy. However, there are safety concerns about the use of
      PQ at the currently recommended dose of 0.75mg/kg in individuals who are glucose-6-phosphate
      dehydrogenase (G6PD) deficient. PQ causes transient but significant haemolysis in G6PD
      deficient individuals; this side-effect is dose dependent. There are indications that a
      lower dosing of PQ may effectively reduce gametocyte carriage but the lowest efficacious
      dose for gametocyte clearance is currently unknown. Recently, the World Health Organization
      changed their recommendation to a low dose of primaquine, 0.25mg/kg. However, there is no
      direct evidence on the extent to which (low dose) PQ prevents malaria transmission to
      mosquitoes and what the lowest efficacious dose is.

      In the current study we aim to identify the lowest efficacious dose of PQ in individuals
      with normal G6PD function. Children with asymptomatic malaria and normal G6PD enzyme
      function will be randomized to treatment with artemether-lumefantrine alone or in
      combination with low doses of PQ. All enrolled individuals will receive a full three-day
      course of AL, and will be randomized to receive a dose of primaquine or placebo with their
      fifth dose of AL. Efficacy will be determined based on gametocyte carriage during follow-up,
      determined by molecular methods, and infectivity to mosquitoes determined by membrane
      feeding assays
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Gametocyte carriage</measure>
    <time_frame>14 days during follow-up</time_frame>
    <safety_issue>No</safety_issue>
    <description>Gametocyte prevalence at enrolment and on days 2, 3, 7, 10, 14 during follow-up.
The duration of gametocyte carriage in days will be estimated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transmission to Anopheles gambiae mosquitoes</measure>
    <time_frame>day 3, day 7, day 10, day 14</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mosquito membrane feeding assays will be used to determine the proportion of infected mosquitoes and the oocyst burden in infected mosquitoes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematological recovery</measure>
    <time_frame>14 days during follow-up</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Haemoglobin concentration will be determined at enrolment and on days 2, 3, 7, 10 and 14 during follow-up. Haemoglobin concentration will be presented as grams per decilitre and as concentration relative to enrolment value.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Malaria</condition>
  <condition>Asymptomatic Malaria</condition>
  <condition>Plasmodium Falciparum</condition>
  <arm_group>
    <arm_group_label>Artemether-Lumefantrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Artemether-Lumefantrine combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Artemether-Lumefantrine-Primaquine 0.25</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Artemether-Lumefantrine with a single dose of 0.25mg/kg primaquine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Artemether-Lumefantrine-Primaquine 0.4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Artemether-Lumefantrine with a single dose of 0.4mg/kg primaquine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether-lumefantrine combination</intervention_name>
    <arm_group_label>Artemether-Lumefantrine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether-Lumefantrine with a single dose of 0.25mg/kg primaquine</intervention_name>
    <arm_group_label>Artemether-Lumefantrine-Primaquine 0.25</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether-Lumefantrine with a single dose of 0.4mg/kg primaquine</intervention_name>
    <arm_group_label>Artemether-Lumefantrine-Primaquine 0.4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 2 years and &lt;15 years

          2. Weight over 10kg

          3. P. falciparum parasitaemia &gt;1,000 parasites and &lt;200,000 parasites/Âµl

          4. P. falciparum gametocytes detected by microscopy

          5. Normal G6PD enzyme function

          6. Informed consent by legally acceptable representative

        Exclusion Criteria:

          1. Enrolled in another study

          2. Fever or history of fever in the last 24 hours

          3. Evidence of severe illness/ danger signs

          4. Known allergy to study medications

          5. Hb &lt; 8g/dL

          6. Started menstruation

          7. Pregnancy or breastfeeding

          8. Antimalarials taken within the last 2 days

          9. Primaquine taken within the last 4 weeks

         10. Blood transfusion within the last 90 days

         11. Non-falciparum malaria co-infection
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfred Tiono, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre National de Recherche et de Formation sur le Paludisme</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Teun Bousema, PhD</last_name>
    <phone>+31243617574</phone>
    <email>teun.bousema@lshtm.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bronner Goncalves</last_name>
    <email>bronner.goncalves@lshtm.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre National de Recherche et de Formation sur le Paludisme</name>
      <address>
        <city>Ouagadougou</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfred Tiono, PhD, MD</last_name>
      <email>t.alfred@fasonet.bf</email>
    </contact>
    <contact_backup>
      <last_name>Andre Lin Ouedraogo, PhD</last_name>
      <email>andre_lin_o@yahoo.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Alfred Tiono, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andre Lin Ouedraogo, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 27, 2013</lastchanged_date>
  <firstreceived_date>September 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Primaquine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether-lumefantrine combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
